ABSTRACT
Objective@# To analyze the clinical characteristics and treatment experience of Vitamin B12 (VB12) deficient patients with recurrent aphthous ulcers (RAU) to improve the clinical efficacy. @*Methods@#A retrospective analysis was performed on 15 cases of recurrent oral ulcers from January 2016 to September 2018. The causes were analyzed according to the patients’ clinical characteristics. @*Results@# In total, 15 patients with RAU had no remission after routine immunotherapy. Further clinical examination suggested that vitamin B12 levels were reduced. The erythrocyte mean corpuscular volume (MCV) was significantly increased, and the average number of red blood cells (RBC) and hemoglobin (Hb) levels were decreased. RAU disappeared after vitamin B12 supplementation. Routine blood work showed that the MCV returned to the normal range, which was statistically significant compared with the pretreatment MCV (P < 0.001). Vitamin B12 serum levels were significantly higher (P < 0.001) than those before treatment.@*Conclusion @#When the main manifestation of vitamin B12 deficiency is recurrent oral ulcer symptoms, dentists should examine the lesions carefully, inquire about the medical history in detail, and perform further serological tests when necessary to avoid the overuse of immunosuppressive drugs for treatment.
ABSTRACT
Objective: To evaluate the curative effects of zinc medicine in the treatment of recurrent aphthous ulcers(RAU). Methods: The randomized controlled trials (RCTs) about the zinc medicine in the treatment of RAU were retrieved from PubMed, CENTRAL, EMbase, CNKI and WANFANG from January 1, 1980 to June 1, 2016, the references included in the study were manually selected. After quality evaluation and material extraction by the reviewer, Meta analysis was done according to the documents and materials by software Stata. Results: 4 RCTs involving 156 patients were included in the study, with 74 cases in the zinc medicine treatment group and 82 cases in the placebo control group. Meta analysis showed that zinc medicine was effective in the treatment of RAU(P＜ 0. 05). Conclusion: Zinc medicine is safe and effective in the treatment of RAU. Zinc deficiency is a risk factor of RAU.
ABSTRACT
Objective To explore and analyze the clinical efficacy and adverse reactions of total glucosides of paeony (TGP) and vitamin B2 in the treatment of recurrent aphthous ulcers (RAU) . Methods 120 patients of RAU were randomly divided into TGP group and vitamin B2 group, 60 cases in each group. The TGP group received TGP capsules after meals, three times a day, 0.6g/d. Vitamin B2 group received vitamin B2 tablets, three times a day, 5mg/d, 8 weeks for one course. The ulcer change, visual analogue scale (VAS) and efficacy were observed. Results After treatment, the VAS scores were significantly reduced in two groups(P<0.05), and the above indicators of TGP group were better than vitamin B2 group(P<0.05). The total efficacy in TGP group was higher than that in vitamin B2 group (P<0.05). There was minor adverse reactions in TGP group and no significant adverse reactions in vitamin B2 group.Conclusion TGP has good efficacy and safety in the treatment of recurrent aphthous ulcers. The TGP has significant effect than that of vitamin B2.
ABSTRACT
Objectives: The primary objective of the following study is to determine and secondary objective is to compare the efficacy and safety of 5% amlexanox oral paste in the treatment of recurrent minor aphthous ulcers and also to evaluate the recurrence rate of aphthous ulcers over a period of 1 year. Materials and Methods: The present study was conducted on 100 patients diagnosed to have recurrent minor aphthous ulcers of which, 50 patients were advised to apply 5% amlexanox oral paste directly on the ulcer 4 times a day for 6 days and the other 50 patients were given placebo paste for the same duration. The baseline parameters were recorded on the first visit which includes ulcer size, pain, erythema and exudation. Efficacy and safety evaluations were made on the 4 th day and 6 th day. In total 30 patients with increased frequency of ulcers were advised to use 5% amlexanox paste for one whole year and the number of ulcers per month was recorded to evaluate any decrease in the recurrence rate. Results: Male patients dominated the study with 73 males and 27 females. The mean age of the total sample was 26.6 years. The amlexanox group showed marked reduction in ulcer size (P < 0.001), significant reduction in the visual analog scale scores of pain (P < 0.001), significant lower scores of erythema and exudation (P < 0.001) when compared to the placebo group on the 6 th day of follow-up. The incidence of recurrence of ulcers was significantly reduced up to the 6 th month, but thereafter recurrence rate slowly increased. Conclusions: Almost 5% of Amlexanox oral paste is clinically beneficial in reducing the pain, erythema, exudation and size of the ulcer over a period of 6 days. There was no definite conclusion drawn with respect to its effect on the recurrence rate of aphthous ulcers over a period of 1 year.